KT&G Announces Shareholder Benefits and Record Sales in 2023

Business by 2FIRSTS.ai
Feb.20.2024
KT&G Announces Shareholder Benefits and Record Sales in 2023
KT&G boosts shareholder value with 2.8 trillion won policy, plans to destroy 3.5 million shares, announces dividends.

According to South Korean media reports on March 16, KT&G Company has decided to further enhance shareholder value by launching a 28 trillion Korean won shareholder return policy and deciding to destroy 3.5 million of its own shares. This 3.25 trillion won destruction is equivalent to 2.6% of the total issued shares. According to the Korea Exchange, KT&G's destruction accounts for 10% of the total amount of self-owned shares destroyed by listed companies that month.

 

According to reports, the board of directors of KT&G has decided to pay a dividend of 4,000 Korean won in 2023. This includes a final half-year dividend of 1,200 Korean won, bringing the total annual dividend to 5,200 Korean won per share, an increase of 200 Korean won from last year. The dividend yield is 5.7%. KT&G held a "Value Day" in November 2023, announcing a new shareholder return policy totaling 28 trillion Korean won to be implemented by 2026 to enhance shareholder value. In 2023, KT&G achieved a record high comprehensive sales revenue of 58.724 trillion Korean won. 

 

Particularly, the overseas cigarette division achieved an annual sales revenue of 11.394 trillion Korean won, breaking a historical record. The combined annual sales revenue of overseas cigarettes, NGP (e-cigarettes), and health foods reached 33.127 trillion Korean won, a 1.1% increase from the previous year. KT&G's goal for this year is to increase comprehensive sales revenue by over 10% and operating profit by over 6%. Sales revenue and operating profit from the three core businesses are expected to increase by over 15% and 31.5% respectively compared to last year.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Korea Rejects 16 Trillion Won Tax-Evasion Claim Over Chinese Synthetic Nicotine
South Korea Rejects 16 Trillion Won Tax-Evasion Claim Over Chinese Synthetic Nicotine
The South Korean government rejected allegations that Chinese synthetic-nicotine e-liquids were linked to about 16 trillion won in tobacco tax evasion, saying China does not ban synthetic nicotine exports and the estimate is difficult to verify, while acknowledging that pre-law synthetic-nicotine inventory is effectively difficult to tax.
Market
Jun.25
Philippine Health Department Pushes Total Vape Ban, With Tobacco-Only Flavor Limit as Alternative
Philippine Health Department Pushes Total Vape Ban, With Tobacco-Only Flavor Limit as Alternative
The Philippine Department of Health said it is pushing for a total ban on vape products. If a full ban is not feasible, DOH officer-in-charge Director Dr. Dominic Maddumba said vape products should at least be limited to plain tobacco flavors to reduce their appeal to minors.
May.06 by 2FIRSTS.ai
Malaysian Tobacco Control Groups Call for Annual 5% Tobacco Tax Hike
Malaysian Tobacco Control Groups Call for Annual 5% Tobacco Tax Hike
According to The Star and The Edge Malaysia, tobacco control groups in Malaysia have urged the government to raise tobacco taxes by at least 5% annually, saying the measure could reduce smoking rates and fund public health and social programmes.
News
May.26
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18
AHA Journal Study: WS-23 Triples Premature Heartbeats, Raising Concerns Over Vape Cooling Agents
AHA Journal Study: WS-23 Triples Premature Heartbeats, Raising Concerns Over Vape Cooling Agents
A University of Louisville research team published a study in an American Heart Association journal suggesting that synthetic cooling agents used in e-cigarettes, including WS-3 and WS-23, may disrupt cardiac electrical activity and increase arrhythmia risk. In animal experiments, WS-23 tripled premature heartbeats.
Jun.16
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13